Part-Time
Dermatologist
Centralia, IL
Posted on 9/19/2025
Schweiger Dermatology Group
1,001-5,000 employees
Medical and cosmetic dermatology services
No salary listed
Mascoutah, IL, USA
Hybrid
 Medical, Clinical & Veterinary (5) |
|---|
| , , , , |
- Board-certified dermatologists, residents (2025 and 2026) and Mohs surgeons
- Full and part-time positions available
- Sign-on Bonus and Relocation Bonus for Full Time
- Highly competitive compensation model
- Comprehensive health benefits, 401(k), Flexible Spending Accounts
- Access to many of the nation's top dermatologists
- Flexible and supportive work environment
- Access to the latest technologies and equipment
- Advanced training programs and education
- Schweiger Dermatology Group is an equal opportunity employer and does not discriminate in its hiring process with applicants, whether internal or external, because of race, creed, color, age, national origin, ancestry, religion, gender, sexual orientation, gender identity, disability, genetic information, veteran status, military status, application for military service or any other class per local, state or federal law.
- Vaccination policy: does not require vaccination for COVID-19 to be considered for employment; some state guidelines may require record of vaccination status on file
- Join Schweiger Dermatology Group as a board-certified dermatologist, resident, or Mohs surgeon to join our growing team. This is an exceptional opportunity to join the largest and fastest growing group dermatology practice in the Northeast with over 110 offices in New York, New Jersey, Pennsylvania, Connecticut, Florida, Illinois, Missouri, and Minnesota.
- Schweiger Dermatology Group offers both medical and cosmetic dermatology services to over 1,500,000 million patients annually.
- Direct Contact Information: Angela Caponi - [email protected]
- Schweiger Dermatology Group is an equal opportunity employer and does not discriminate in its hiring process with applicants...
- None specified
Schweiger Dermatology Group provides medical and cosmetic dermatology services to a wide patient base. It treats conditions like acne and skin cancer, performs mole removal, and offers cosmetic procedures such as laser treatments, Botox, and hair restoration. The company runs in-person visits and telemedicine appointments, with same-day access to care to improve convenience. Treatments are delivered by dermatology clinicians during visits or virtual consultations, and safety protocols are emphasized, especially during the COVID-19 era. Compared with competitors, Schweiger Dermatology stresses a patient-centric model with broad service offerings, quick access, and multiple care formats (in-office and telemedicine). Its goal is to make dermatology care safe, accessible, and comprehensive for routine skin care and specialized medical treatments.
Company Size
1,001-5,000
Company Stage
Growth Equity (Venture Capital)
Total Funding
$177.7M
Headquarters
New York City, New York
Founded
2010
Simplify's Take
What believers are saying
- Acquired United Skin Specialists, adding 10 Midwest offices in 2024.
- Expanded Florida with ClearlyDerm's five South offices recently.
- Partners with Obagi for ALOHA Phase 4 study starting early 2026.
What critics are saying
- Local doctors defect post-ClearlyDerm acquisition, eroding Florida retention.
- NavaDerm's NYC practices capture Schweiger's Botox revenue dominance.
- FTC antitrust blocks expansions, forces divestitures of 2024 acquisitions.
What makes Schweiger Dermatology Group unique
- Leads with 36,000+ Mohs surgeries in 2025 for skin cancer.
- Offers same-week appointments across 90+ locations nationwide.
- Named to Inc. 5000 fastest-growing list for ninth year in 2025.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↑ 2%2 year growth
↑ 4%Obagi Medical, part of Waldencast plc, has partnered with Schweiger Dermatology for its ALOHA Programme to generate real-world evidence for Obagi saypha MagIQ injectable. Schweiger was selected for its clinical excellence and extensive national network. The collaboration includes two initiatives: a Phase 4 clinical study led by Dr David Goldberg in Hackensack, and a real-world evaluation programme across select Schweiger aesthetic locations. Programme activities are expected to begin in early 2026. Schweiger will present initial findings at internal leadership meetings and industry conferences. Dr Goldberg noted the partnership aligns with Schweiger's focus on accessible, high-quality care, whilst Drew Fine, Obagi's US General Manager, emphasised the company's commitment to launching the injectable with robust clinical evidence.
NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Schweiger Dermatology Group, a leading provider of dermatology and allergy care, is proud to announce it has been awarded eight Accolades by Castle Connolly. Accolades recognize health systems, hospitals and physician practices that deliver exceptional healthcare through their highly esteemed Castle Connolly Top Doctor physicians.Schweiger Dermatology Group received the following Castle Connolly Accolades for 2025:#1 for Dermatology in New York#1 for Dermatology in New York City#1 for Dermatology in Pennsylvania#1 for Dermatology in Philadelphia#1 for Dermatology in New Jersey#3 for Dermatology in Florida#2 Nationally in Dermatology#2 Nationally in Cosmetic and Reconstructive CareIn addition, 61 Schweiger Dermatology Group physicians have been recognized as Castle Connolly Top Doctors for 2025. This prestigious honor highlights the exceptional expertise and dedication of medical professionals across a growing number of specialties and locations nationwide. Castle Connolly is renowned for its rigorous selection process for Top Doctors, which involves peer nominations, research and a thorough vetting process by a physician-led research team."We are dedicated to delivering the highest level of care and innovation in dermatology and allergy," said Dr. Eric Schweiger, founder and CEO of Schweiger Dermatology Group
DSA was part of the NavaDerm platform formed in 2018.
FORT LAUDERDALE, Fla. and NEW YORK, Nov. 15, 2024 /PRNewswire/ -- NavaDerm Partners, LLC ("NavaDerm" or the "Company"), a dermatology platform and portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), announced the exit of Dermatology and Surgery Associates ("DSA") to Schweiger Dermatology Group ("SDG"). DSA was part of the NavaDerm platform formed in 2018. Vera Abramova, Chief Financial Officer of NavaDerm Partners, LLC said, "We are pleased to announce this is the third practice sold to SDG in the past year. Our remaining flagship practices - Laser Skin Surgery of New York with locations at 34th Street (NYC) and Southampton and our growing Spring Street practice with NYC locations in SoHo and Uptown, continue to benefit from the tailwinds in cosmetic dermatology."
Schweiger Dermatology Group has expanded in Florida by acquiring ClearlyDerm, a leading dermatology practice founded by Dr. Andrea Colton. This acquisition adds five new offices in South Florida, located in Boca Raton, West Boca Raton, Fort Lauderdale, Boynton Beach, and Delray Beach. Dr. Colton and her team, known for their patient-first philosophy, will join Schweiger Dermatology Group, enhancing their presence and services in the region.